Ijraset Journal For Research in Applied Science and Engineering Technology
Authors: Arman Sayyad, Amrata Mantri, Shrikrishna Baokar, Rajendra Patil
DOI Link: https://doi.org/10.22214/ijraset.2025.66446
Certificate: View Certificate
The application of nanotechnology in cancer therapy has revolutionized oncology by enabling precise, targeted, and minimally invasive treatment modalities. Nanoparticles, with their unique physicochemical properties, have emerged as versatile tools for improving drug delivery, imaging, and therapeutic efficacy. This review explores the role of nanotechnology in overcoming traditional challenges in cancer treatment, such as systemic toxicity, poor bioavailability, and resistance to chemotherapy. Key advancements include the development of multifunctional nanoparticles capable of simultaneous drug delivery and diagnostic imaging, as well as nanoscale systems designed to bypass biological barriers and deliver therapeutics directly to tumor sites. Additionally, nanotechnology has paved the way for innovative approaches like photothermal and photodynamic therapies, which harness light-mediated mechanisms to eradicate cancer cells with minimal damage to healthy tissues. Despite these advancements, challenges such as nanoparticle biocompatibility, scalability, and regulatory approval remain critical hurdles to widespread clinical adoption. This review provides a comprehensive overview of the current state of nanotechnology in cancer therapy, highlights its transformative potential, and discusses future directions for research and clinical translation. By bridging the gap between engineering and medicine, nanotechnology promises to redefine cancer care and improve patient outcomes.
I. INTRODUCTION
Cancer is one of the leading causes of death worldwide, and despite significant progress in treatment methods, it remains a challenging disease to manage. Traditional cancer therapies, such as chemotherapy and radiation, often come with severe side effects because they harm healthy tissues alongside cancerous ones. Additionally, issues like drug resistance and poor drug distribution in the body further limit the effectiveness of these treatments. Nanotechnology has emerged as a groundbreaking approach to address these challenges in cancer therapy. By using extremely small particles—called nanoparticles—scientists have developed tools that can deliver drugs more precisely to cancer cells, minimizing harm to healthy tissues. These nanoparticles are designed to take advantage of unique features of tumors, such as their leaky blood vessels, to ensure better drug delivery.
In recent years, nanotechnology has also introduced innovative treatment strategies like photothermal therapy, which uses light to heat and kill cancer cells, and photodynamic therapy, which activates special molecules to destroy tumors. Some nanoparticles are even multifunctional, meaning they can deliver drugs, help doctors image tumors, and monitor treatment progress—all at the same time. Although these advancements are promising, challenges like ensuring the safety of nanoparticles, producing them at a large scale, and gaining regulatory approval for clinical use still need to be overcome. This paper explores how nanotechnology is transforming cancer therapy, the progress made so far, and the steps needed to bring these innovative treatments into everyday medical practice.1,2,3,4
A. Available Methods and Treatments for Cancer
Cancer treatment traditionally relies on three primary approaches: surgery, chemotherapy, and radiation therapy. Each method has its benefits and limitations:
B. How Nanotechnology Can Transform Cancer Treatment
Nanotechnology offers innovative solutions to many of the challenges faced by traditional cancer treatments. By designing materials at the nanoscale, scientists can develop highly precise tools for drug delivery, imaging, and therapy. Here’s how nanotechnology addresses key issues in cancer treatment:
1) Targeted Drug Delivery
2) Improved Drug Solubility and Bioavailability
3) Overcoming Drug Resistance
4) Crossing Biological Barriers
5) Theranostics: Combining Therapy and Diagnostics
6) Photothermal and Photodynamic Therapy
7) Overcoming Metastatic Cancer Challenges
8) Reducing Systemic Toxicity
C. Key Nanotechnology Platforms in Cancer Therapy
Nanotechnology provides a multifaceted approach to improving cancer therapy by addressing the limitations of existing methods and offering innovative solutions. It holds the potential to make cancer treatment more effective, less toxic, and tailored to individual patient needs.
II. ADVANTAGES AND DISADVANTAGES OF NANOTECHNOLOGY IN CANCER THERAPY
A. Advantages
B. Disadvantages
III. BALANCING BENEFITS AND CHALLENGES
While nanotechnology offers transformative advantages in cancer therapy, addressing its disadvantages is essential for widespread clinical adoption. Continued research, better regulatory frameworks, and advancements in manufacturing processes will be crucial to overcoming these challenges and unlocking the full potential of nanotechnology in cancer care.17,18
Nanotechnology represents a paradigm shift in the way cancer is treated, offering innovative solutions to longstanding challenges in oncology. By enabling precise drug delivery, reducing systemic toxicity, and introducing multifunctional therapeutic platforms, nanotechnology has the potential to significantly improve patient outcomes. Techniques such as photothermal and photodynamic therapies, as well as theragnostic nanoparticles, highlight the versatility and promise of nanoscale systems in cancer care. Despite these advancements, hurdles like biocompatibility, manufacturing scalability, regulatory approval, and long-term safety must be addressed to ensure widespread clinical adoption. Continued interdisciplinary collaboration between scientists, clinicians, and regulatory bodies is essential to overcome these barriers and translate laboratory breakthroughs into real-world treatments. As research progresses, nanotechnology holds the potential to redefine cancer therapy, transforming it into a more effective, personalized, and less invasive approach. By bridging the gap between engineering and medicine, nanotechnology not only enhances current treatment options but also paves the way for a future where cancer care is safer and more efficient for patients worldwide.19,20
[1] M. Ferrari, \"Cancer nanotechnology: Opportunities and challenges,\" Nature Reviews Cancer, vol. 5, no. 3, pp. 161–171, Mar. 2005, doi: 10.1038/nrc1566. [2] J. Shi, A. R. Votruba, O. C. Farokhzad, and R. Langer, \"Nanotechnology in drug delivery and tissue engineering: From discovery to applications,\" Nano Letters, vol. 10, no. 9, pp. 3223–3230, Sep. 2010, doi: 10.1021/nl102184c. [3] K. Greish, \"Enhanced permeability and retention (EPR) effect for anticancer nanomedicine: Paradigm, pitfalls, and prospects,\" Cancer Nanotechnology, vol. 1, no. 1, pp. 89–97, Dec. 2010, doi: 10.1007/s12645-010-0016-z. [4] J. N. Anker et al., \"Biosensing with plasmonic nanosensors,\" Nature Materials, vol. 7, no. 6, pp. 442–453, Jun. 2008, doi: 10.1038/nmat2162. [5] S. Wilhelm et al., \"Analysis of nanoparticle delivery to tumours,\" Nature Reviews Materials, vol. 1, no. 5, May 2016, Art. no. 16014, doi: 10.1038/natrevmats.2016.14. [6] A. J. Welch and M. J. van Gemert, Optical-Thermal Response of Laser-Irradiated Tissue, New York, NY, USA: Springer, 2011, doi: 10.1007/978-90-481-8831-4. [7] P. C. Ma et al., \"Functionalized carbon nanotubes for nanomedicine applications,\" Materials Science and Engineering: C, vol. 27, no. 5–8, pp. 754–761, Jun. 2007, doi: 10.1016/j.msec.2006.11.001. [8] M. P. Monopoli et al., \"Biomolecular coronas provide the biological identity of nanosized materials,\" Nature Nanotechnology, vol. 7, no. 12, pp. 779–786, Dec. 2012, doi: 10.1038/nnano.2012.207. [9] M. J. Sailor and J. H. Park, \"Hybrid nanoparticles for detection and treatment of cancer,\" Advanced Materials, vol. 24, no. 28, pp. 3779–3802, Jul. 2012, doi: 10.1002/adma.201201752. [10] A. E. Nel et al., \"Understanding biophysicochemical interactions at the nano-bio interface,\" Nature Materials, vol. 8, no. 7, pp. 543–557, Jul. 2009, doi: 10.1038/nmat2442. [11] L. Zhang et al., \"Nanoparticles in medicine: Therapeutic applications and developments,\" Clinical Pharmacology & Therapeutics, vol. 83, no. 5, pp. 761–769, May 2008, doi: 10.1038/sj.clpt.6100400. [12] H. Cabral et al., \"Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours,\" Nature Nanotechnology, vol. 6, no. 12, pp. 815–823, Dec. 2011, doi: 10.1038/nnano.2011.166. [13] J. Conde, N. Oliva, Y. Zhang, and N. Artzi, \"Nanomaterials for reprogramming cell fate: From differentiation to dedifferentiation,\" Advanced Materials, vol. 28, no. 5, pp. 887–928, Feb. 2016, doi: 10.1002/adma.201503308. [14] T. P. Piroyan et al., \"Gold nanoparticles for cancer theranostics,\" Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1865, no. 6, Jun. 2019, Art. no. 194754, doi: 10.1016/j.bbcan.2019.194754. [15] R. Singh and J. W. Lillard, Jr., \"Nanoparticle-based targeted drug delivery,\" Experimental and Molecular Pathology, vol. 86, no. 3, pp. 215–223, Jun. 2009, doi: 10.1016/j.yexmp.2009.01.004. [16] K. Yang et al., \"Graphene in cancer therapy: Mechanisms, applications, and future trends,\" Theranostics, vol. 2, no. 3, pp. 271–282, Apr. 2012, doi: 10.7150/thno.3642. [17] C. G. J. Stevens et al., \"Quantum dots for cancer imaging,\" Trends in Biotechnology, vol. 31, no. 8, pp. 455–463, Aug. 2013, doi: 10.1016/j.tibtech.2013.05.002. [18] H. S. Muddineti, M. Ghosh, and R. Biswas, \"Current trends in using polymer-coated gold nanoparticles for cancer therapy,\" International Journal of Molecular Sciences, vol. 16, no. 4, pp. 7418–7437, Apr. 2015, doi: 10.3390/ijms16047418. [19] A. Wicki et al., \"Nanomedicine in cancer therapy: Challenges and opportunities,\" Current Opinion in Biotechnology, vol. 46, pp. 150–158, Apr. 2017, doi: 10.1016/j.copbio.2017.02.005. [20] S. Dreaden et al., \"The evolving role of nanoparticles in cancer therapy,\" Nature Reviews Cancer, vol. 16, no. 3, pp. 250–262, Mar. 2016, doi: 10.1038/nrc.2016.19.
Copyright © 2025 Arman Sayyad, Amrata Mantri, Shrikrishna Baokar, Rajendra Patil. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Paper Id : IJRASET66446
Publish Date : 2025-01-09
ISSN : 2321-9653
Publisher Name : IJRASET
DOI Link : Click Here